In this review article, we will present the possible links between inflammasome-mediated cytokines, obesity-associated NASH, and HCC development, and we will also discuss approaches to using IL-1β and IL-18 as therapeutic targets in the context of HCC. This evidence concerns the gene IL18 and metabolic dysfunction-associated steatohepatitis.